Connect
← Return to Tymlos Side effects
Discussion
Osteoporosis & Bone Health | Last Active: 2 hours ago | Replies (74)
Comment receiving replies
@willowmena
You may like to read this article: https://www.biospace.com/radius-announces-update-on-tymlos-abaloparatide-label published 23 December 2023: it starts with
"Radius Health, Inc. (“Radius” or the “Company”) (NASDAQ: RDUS) today announced that the U.S. Food and Drug Administration (FDA) has approved updates to the TYMLOS label.
FDA approved the removal of the boxed warning from the TYMLOS label, effective December 22, 2021
The boxed warning had referred to the potential risk of osteosarcoma
Action follows review of long-term post-marketing data for TYMLOS and PTH class of drugs."
Replies to "@willowmena You may like to read this article: https://www.biospace.com/radius-announces-update-on-tymlos-abaloparatide-label published 23 December 2023: it starts with..."
Connect
@wilweten I guess it depends on what is considered "long term" for post marketing. I believe Tymlos hit the market in 2017 and 4 years later the boxed warning is removed. I don't feel comfortable with characterizing that as long-term, as much as I want it to be accurate. Even with misgivings, I am continuing Tymlos, albeit at 70 mcg. With severe osteoporosis and malabsorption gastric issues, I don't have many options.